Please assess the completion status of the following clinical trial:

Trial Title: Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who completed 28 days of study treatment in Protocol 501-CL-003.~2. No significant safety or tolerability concerns from the patient's participation of Protocol 501-CL-003 as determined by the Investigator.~3. Received medical monitor approval for enrollment into this study.~4. Patients receiving maintenance corticosteroids may be enrolled, as long as the corticosteroids have been administered at a stable dose and the Investigator does not foresee the need to change the steroid dose during study participation. Patients should remain on this stable corticosteroid dose during study participation.~5. Women of child-bearing potential must have a negative serum pregnancy test at the Day 28 assessment in Protocol 501-CL-003. (Childbearing potential is defined as any woman who has not been surgically sterilized and is pre-menopausal or peri-menopausal i.e., any menstrual flow within 12 months of Screening Visit A for Protocol 501-CL-003).~6. Women of child-bearing potential must agree to practice a medically approved form of contraception (one of the following must be used: condoms (male or female) with a spermicidal agent, diaphragm or cervical cap with a spermicidal agent, IUD,hormonal contraception, abstinence).~7. Willing and able to provide written informed consent.~Exclusion Criteria:~1. Women who are pregnant and/or lactating.~2. Use of the following drugs or treatments:~   * Rituximab~  * Azathioprine, Cyclosporine A, or other immunosuppressant therapy~  * Aspirin, Aspirin-containing compounds, Salicylates,Anticoagulants, Non-steroidal anti-inflammatory drugs(NSAIDs)(including Cyclooxygenase-2 \[COX-2\] specific NSAIDs), clopidogrel; ticlopidine; and any drugs that affect platelet function.~  * Danazol~  * Rh0(D) immune globulin (WinRho®) or intravenous immunoglobulin (IVIG).~3. Inability to comply with protocol requirements or give informed consent, as determined by the Investigator.~For more information regarding inclusion/exclusion criteria, please see record for AKR 501-CL-003 Protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (double-blind) (Type: EXPERIMENTAL): None
- Avatrombopag tablets (open-label) (Type: EXPERIMENTAL): None
- Avatrombopag tablets (double-blind) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).